ReproNovo Aps

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, ReproNovo Aps sits in the upper half of US sponsors by registered trial count (#7,388 of 15,742 sponsors by registered trial count).

1 total trials 1 currently recruiting early-phase tilt upper half by trial count

ReproNovo Aps: 1 sponsored US clinical trial, 1 recruiting.

ReproNovo Aps sponsors 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Semen Quality, with 1 trials.

Mid-pack sponsor footprint

ReproNovo Aps is in the upper half of sponsors by trial count (#7,388 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.

Open and recent trials

1 total, page 1 of 1

RECRUITING Phase 2

A Clinical Trial Evaluating the Efficacy and Safety of Leflutrozole on Testicular Function

NCT06993155

Phase Distribution

PhaseTrial count
Phase 2 1

Therapeutic Areas

Semen Quality 1

What is open in the ReproNovo Aps pipeline

1 recruiting of 1 indexed (100% open).

Phase mix: 0 late (III/IV) vs 1 early (I/II) (early-phase heavy).

Top condition: Semen Quality (1 trial), 0 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

ReproNovo Aps: open-pipeline peers nationwide

Peers matched on 1 registered trials and 100% open enrollment, not the therapeutic-area sidebar.

ReproNovo Aps sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 012345 0%50%100%150% Total trials Recruiting share ReproNovo Aps1200 Pharma1ST Biotherapeutics3 Waves Wellness3EO HealthAAVantgarde Bio SrlAcorn BiolabsAcrivon TherapeuticsADARx Pharmaceuticals
ReproNovo Aps sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

ReproNovo Aps sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1 trials (± recruiting share)

Sponsors near 100% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this ReproNovo Aps page

1 registered trials is a research-attention snapshot, not an endorsement of ReproNovo Aps or any single study.

  • 1 of ReproNovo Aps's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Semen Quality is the condition ReproNovo Aps studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Semen Quality trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

ReproNovo Aps pipeline card: 1 registered trials from official public datasets.Report a data error.